Figure S1. Patient enrollment flow chart. Two hundred and two patients were screened for enrollment; 55 patients were screen failures, resulting in 147 patients being enrolled (N=72 in the rosuvastatin arm, N=75 in the placebo arm). *hsCRP <2 mg/L; **CD8+ T-cell expression of CD38 and HLA-DR antigens <19%; †Patient found to have very high coronary calcium score by computed tomography on same day as screening, deemed unethical for patient to be potentially randomized to placebo. CrCl, creatinine clearance; LFTs, liver function tests; LDL, low-density lipoprotein; hsCRP, high-sensitivity C-reactive protein; TG, triglycerides